Skip to content
Screener

Twist Bioscience Corporation TWST Reportable Segment — Revenue

Similar metrics at other companies

Rimini Street, Inc. logo
RMNIReportable Segment — Revenue
$105.47M+1.2%
Lifecore Biomedical, Inc. logo
LFCRReportable Segment — Revenue
$34.17M
Akamai Technologies logo
AKAMReportable Segment — Revenue
$1.1B+5.4%
Analog Devices logo
ADIReportable Segment — Revenue
$3.62B+37.2%
Adobe logo
ADBEReportable Segment — Revenue
$6.62B+12.7%
Credo Technology Group Holding Ltd logo
CRDOReportable Segment — Revenue
$437M+157%

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$6.84B+338%
Enterprise value$6.83B+370%
P/S16.7×+12.4×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0001581280-26-000040
(in thousands)Three months ended March 31, 2026Three months ended March 31, 2025Six months ended March 31, 2026Six months ended March 31, 2025
Revenues$110,715$92,793$214,413$181,506
Costs and expenses:
Cost of revenues[1]$47,402$40,373$91,408$80,744
Research and development expenses[1]17,36619,95232,71238,078
Selling, general and administrative expenses[1]59,25547,298117,03493,786
Litigation settlement costs, net of recoveries7,2057,205
Depreciation and amortization6,4146,40212,60812,784
Stock-based compensation expense18,93620,32832,20932,319

Item 1. Financial Statements (unaudited)

FAQ

What is Twist Bioscience Corporation's reportable segment — revenue?
Twist Bioscience Corporation (TWST) reported reportable segment — revenue of $110.72M in Q1 2026.
How has Twist Bioscience Corporation's reportable segment — revenue changed year-over-year?
Twist Bioscience Corporation's reportable segment — revenue increased by 19.3% year-over-year, from $92.79M to $110.72M.
What does reportable segment — revenue mean?
Represents the total gross inflow of economic benefits arising from the ordinary operating activities of the reportable business segment. It reflects the market demand for the segment's products or services and serves as the primary indicator of top-line growth and market penetration.

Ask your AI about Twist Bioscience Corporation's reportable segment — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude